(S (NP (EX There)) (VP (VBZ remains) (NP (NP (JJ much) (NN uncertainty)) (PP (IN about) (NP (NP (DT the) (JJ relative) (NN effectiveness)) (PP (IN of) (NP (NP (JJ different) (JJ nonpharmaceutical) (NNS interventions)) (PRN (-LRB- -LRB-) (NP (NNP NPIs)) (-RRB- -RRB-)))) (PP (IN against) (NP (NNP COVID-19) (NN transmission))))))) (. .))
(S (NP (JJ Several) (NNS studies)) (VP (VBP attempt) (S (VP (TO to) (VP (VB infer) (NP (NNP NPI) (NN effectiveness)) (PP (IN with) (NP (NN cross-country) (, ,) (JJ data-driven) (NN modelling))) (, ,) (PP (IN by) (S (VP (VBG linking) (PP (IN from) (NP (NNP NPI) (NN implementation) (NNS dates))) (PP (TO to) (NP (NP (DT the) (JJ observed) (NN timeline)) (PP (IN of) (NP (NP (NNS cases) (CC and) (NNS deaths)) (PP (IN in) (NP (DT a) (NN country)))))))))))))) (. .))
(S (NP (DT These) (NNS models)) (VP (VBP make) (NP (JJ many) (NNS assumptions))) (. .))
(S (NP (JJ Previous) (NN work)) (VP (VP (ADVP (RB sometimes)) (VBZ tests) (NP (NP (DT the) (NN sensitivity)) (PP (TO to) (NP (NP (NNS variations)) (PP (IN in) (NP (JJ explicit) (JJ epidemiological) (NN model) (NNS parameters))))))) (, ,) (CC but) (VP (ADVP (RB rarely)) (VBZ analyses) (NP (NP (DT the) (NN sensitivity)) (PP (TO to) (NP (NP (DT the) (NNS assumptions)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN made) (PP (IN by) (NP (NP (DT the) (NN choice) (NP (DT the))) (PP (IN of) (NP (NN model) (NN structure)))))))))))) (PRN (-LRB- -LRB-) (NP (JJ structural) (NN sensitivity) (NN analysis)) (-RRB- -RRB-)))) (. .))
(S (NP (JJ Such) (NN analysis)) (VP (MD would) (VP (VB ensure) (SBAR (IN that) (S (NP (NP (DT the) (NNS inferences)) (VP (VBN made))) (VP (VBP are) (ADJP (JJ consistent)) (PP (IN under) (NP (JJ plausible) (JJ alternative) (NNS assumptions)))))))) (. .))
(S (PP (IN Without) (NP (PRP it))) (, ,) (NP (NNP NPI) (NN effectiveness) (NNS estimates)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB guide) (NP (NN policy)))))))) (. .))
(S (NP (PRP We)) (VP (VBP investigate) (NP (NP (CD four) (NN model) (NNS structures)) (ADJP (JJ similar) (PP (TO to) (NP (DT a) (JJ recent) (JJ state-of-the-art) (NNP Bayesian) (JJ hierarchical) (NN model)))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP (DT the) (NNS models)) (VP (VBP differ) (ADVP (RB considerably)) (PP (IN in) (NP (NP (DT the) (NN robustness)) (PP (IN of) (NP (PRP$ their) (NNP NPI) (NN effectiveness) (NNS estimates))) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ epidemiological) (NNS parameters)) (CC and) (NP (DT the) (NN data)))))))))))) (. .))
(S (S (VP (VBG Considering) (NP (NP (RB only) (DT the) (NNS models)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (JJ good) (NN robustness)))))))) (, ,) (NP (PRP we)) (VP (VBP find) (SBAR (IN that) (S (NP (NP (NNS results)) (CC and) (NP (JJ policy-relevant) (NNS conclusions))) (VP (VBP are) (ADJP (RB remarkably) (JJ consistent)) (PP (IN across) (NP (DT the) (ADJP (RB structurally) (JJ different)) (NNS models))))))) (. .))
(S (NP (PRP We)) (VP (ADVP (VBP further)) (VB investigate) (NP (DT the) (JJ common) (NNS assumptions) (SBAR (IN that) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT an) (NNP NPI)))) (VP (VBZ is) (ADJP (JJ independent) (PP (IN of) (NP (NP (DT the) (NN country)) (, ,) (NP (DT the) (NN time)) (, ,) (CC and) (NP (JJ other) (JJ active) (NNP NPIs)))))))))) (. .))
(S (NP (PRP We)) (VP (ADVP (RB mathematically)) (VBP show) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (VP (VB interpret) (NP (NN effectiveness) (NNS estimates)) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS assumptions)) (VP (VBP are) (VP (VBN violated)))))))))) (. .))
